GSK stock gains two oncology milestones in Japan and the US
Published on 11/21/2026 at 11:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGSK advances its oncology pipeline
- Japan granted orphan drug designation to velzatinib for gastrointestinal stromal tumours.
- The US Food and Drug Administration granted accelerated approval to Nelkarmi for previously treated ALK-positive non-small cell lung cancer.
- Both regulatory decisions strengthen GSK's focus on targeted oncology medicines.
GSK secured two regulatory milestones in oncology during the week of November 16-20, 2026. Japan granted orphan drug designation to velzatinib on November 19 for gastrointestinal stromal tumour, while the US Food and Drug Administration approved Nelkarmi on November 17 for certain previously treated patients with ALK-positive non-small cell lung cancer.
According to GSK, the Japanese designation covers velzatinib, a selective KIT inhibitor being developed for GIST. The company said the designation was supported by data from the ongoing phase I/Ib StrateGIST 1 trial and that phase III studies are under way in first- and second-line advanced or metastatic disease.
A separate GSK US release said the FDA granted accelerated approval to Nelkarmi, also known as neladalkib, ahead of the agency's November 27 target action date. The approval applies to adults with locally advanced or metastatic ALK-positive non-small cell lung cancer after prior ALK-directed treatment. The decision was based on results from the phase I/II ALKOVE-1 trial.
GSK stock traded at 21.75 euros on Lang & Schwarz at 11:45 CET on Saturday, November 21, 2026.
GSK plc at a glance
- Company: GSK plc
- ISIN: GB00BN7SWP63
- Xetra symbol: GS71
- Latest quote: 21.75 euros on Lang & Schwarz, November 21, 2026, 11:45 CET
- Xetra close: 22.91 euros on Friday, November 13, 2026
Broader UK equities can be followed through Current market reports.
More news and analyses on GSK stock.
